Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma

• Nobukazu Fujimoto ,

  * E-mail: nobufujimot@gmail.com

  Affiliation Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan

  ⨯
• Kei Ohnuma,

  Affiliation Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan

  ⨯
• Keisuke Aoe,

  Affiliation Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan

  ⨯
• Osamu Hosono,

  Affiliation Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan

  ⨯
• Taketo Yamada,

  Affiliation Department of Pathology, Keio University school of Medicine, Tokyo, Japan

  ⨯
• Takumi Kishimoto,

  Affiliation Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan

  ⨯
• Chikao Morimoto

  Affiliation Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan

  ⨯